OBJECTIVE: To probe into the clinical effect of different doses of recombinant human growth hormone（ rh GH） combined with small dose of stanozolol in the treatment of non-growth hormone deficient dwarfism. METHODS:Totally 99 children with non-growth hormone deficient dwarfism admitted into the Affiliated Hospital of Hebei University from Jan. 2017 to Jan. 2018 were selected and divided into group A

group B and group C via random number table

with 33 cases in each group. Group A was treated with small dose of stanozolol

group B was given small dose of rhGH based on group A

while group C was given large dose of rhGH based on group A. The clinical efficacy after 1-year treatment

height（ Ht） before and after treatment

growth velocity（ GV）

height standard deviations（ Ht SDS）

increment of bone age（ ΔBA）

increment of height age（ ΔHA）

ΔHA/ΔBA and incidences of adverse drug reactions were compared among three groups. RESULTS: The total effective rates of group A

group B and group C were respectively 69. 70%（ 23/33）

81. 82%（ 27/33） and 93. 94%（ 31/33）

with statistically significant differences（ P < 0. 05）. After treatment

the Ht

GV and Ht SDS of three groups were significantly increased

those of group C were significantly higher than those of group B

and those of group B were significantly higher than those of group A

with statistically significant differences（ P < 0. 05）. After treatment

there were no statistical significance in differences in ΔBA

ΔHA and ΔHA/ΔBA among three groups（ P > 0. 05）. During treatment

the incidences of adverse drug reactions of group A

group B and group C were respectively 6. 06%（ 2/33）

12. 12%（ 4/33） and15. 15%（ 5/33）

the differences among groups were not statistically significant（ P > 0. 05）. CONCLUSIONS: The efficacy of rhGH combined with small dose of stanozolol in the treatment of non-growth hormone deficient dwarfism in children is remarkable

which can rapidly improve the GV and height of children

and the combination of large-dose rhGH with small-dose stanozolol is more effective. rh GH does not accelerate skeletal maturation

does not affect the growth potential

and has a good therapeutic safety.